SLC5A2 and heart failure: The Kaplan–Meier rates were lower in those treated with SGLT2 inhibitors for both first hospitalisation for heart failure (5.0 vs 7.6), for all-cause death (4.0 vs 9.5) and stroke (1.3 vs 1.9) (Table 2).